Gain Therapeutics’ Post

Curious about how organoids can benefit your drug discovery pipeline? Check out this webinar for a discussion on current research challenges and future directions: https://lnkd.in/g2KjSQuC

Satellos Bioscience Doses the First Patient with SAT-3247 Under the P-I Study for Duchenne Muscular Dystrophy  #satellos #sat3247 #duchennemusculardystrophy #clinicaltrial #firstpatientdosing #phase1 #smallmolecule

Avidity Biosciences (RNA) leads in RNA therapeutics with Del-desiran (AOC 1001), targeting myotonic dystrophy type 1. Pivotal trial soon; approval could significantly boost earnings. Partnership with Bristol Myers Squibb, worth up to $2.3 billion, expands collaboration. Major clinical update for AOC 1001 expected by mid-2025; success could validate Avidity’s platform. Bullish on RNA above $24.00-$24.50, targeting $34.00-$35.00. Avidity's innovative approach presents significant growth potential. #AvidityBiosciences #RNA #Biotech #MyotonicDystrophy #ClinicalTrials #Innovation #Investing

GOLD in Action⭐ In the highlighted publication, the mechanism of action of the mGlu7 receptor antagonist XAP044 was elucidated by combining a structure‒activity relationship study, molecular modeling and docking experiments. The team performed docking studies using the CCDC's protein-ligand docking software GOLD, integrated within Dassault Systèmes’ BIOVIA therapeutics design software #DiscoveryStudio. 🔗https://lnkd.in/e5qVdJ67 #GOLD #docking

New publication! We’ve been working with John (Jay) Schneekloth, a leading expert in RNA-targeted drug discovery, to use our MAGNA technology to probe the interactions between the PreQ1 bacterial riboswitch and its natural ligand or a synthetic small molecule.   Published as a preprint on bioRxiv and submitted for publication in a high profile journal, the paper shows how we were able to use MAGNA to provide novel insights into the mechanisms of action of these two ligands upon the target RNA at a single molecule level.    We found that while both ligands stabilized the RNA structure, they did so through different mechanisms - a distinction that was not possible to detect using bulk measurement techniques.    These results demonstrate the capabilities of MAGNA to deliver valuable data about individual dynamic molecular interactions at scale, supporting lead selection in the development of novel RNA-targeted therapeutics.   Read the paper to get the full story: https://lnkd.in/df-tQb-9    #RNA #DrugDiscovery #DrugDevelopment #interactomics 

The BD Monoclonal Center was the first one to combine FACS and monoclonal antibody techniques together at a commercial scale. Read the blog to learn more about how the history of FACS and BD Biosciences is intertwined.  https://lnkd.in/gK33AYGb #FactsaboutFACS #Flowcytometry #FACS #BDBiosciences

You most likely have incomplete data sets from your current preclinical imaging techniques. Cryo-Fluorescence Tomography (CFT) provides unmatched visualization of on- and off-target drug distribution in whole animals. Best of all, CFT integrates seamlessly into your existing in vivo imaging workflows. This 3D CFT image was obtained from a 1µg dose of ZW800-1-labeled FAP-targeting small molecule. The data shows drug preferential uptake in the tumor with minimal uptake in other organs and tissues. If you look closely, you can also see on-target signal in the joints! Discover more with CFT: https://bit.ly/3KuhQYx #fluorescenceimaging #biotechnology #drugbiodistribution #science Copyright 2023 Ratio Therapeutics Inc., used with permission

Check out this absolutely stunning study on ::several:: CDK/drug complexes, structures resolved to <2Å resolution by cryo-EM. If your institution is still hesitant to invest in cryo-EM for drug discovery, this study might help change their minds. #drugdiscovery #cryoEM #CDKcomplexes

Studying protein structure, dynamics, and interactions is pivotal for understanding disease mechanisms and to advance drug discovery and development. Scientists at the Tatyana Polenova's Laboratory, University of Delaware, USA, are using #NMR spectroscopy to study large protein assemblies, advancing the understanding of disease mechanisms for the development of new therapeutics. Learn more: https://lnkd.in/dM95fsax #MakeMRmoreRelevant #Spectroscopy #UniversityofDelaware

If you're looking to learn from the past and 𝗽𝗿𝗼𝗽𝗲𝗹 𝘆𝗼𝘂𝗿 𝗺𝗮𝗰𝗿𝗼𝗽𝗵𝗮𝗴𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝘁𝗼 𝗰𝗹𝗶𝗻𝗶𝗰, look no further than the 𝟲𝘁𝗵 𝗠𝗮𝗰𝗿𝗼𝗽𝗵𝗮𝗴𝗲-𝗗𝗶𝗿𝗲𝗰𝘁𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗦𝘂𝗺𝗺𝗶𝘁!   𝗙𝘂𝗹𝗹 𝗔𝗴𝗲𝗻𝗱𝗮 𝗛𝗲𝗿𝗲 ➡️ https://ter.li/3pt48z   𝗨𝗻𝗶𝘁𝗶𝗻𝗴 𝟲𝟬+ 𝗯𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮 𝗮𝗻𝗱 𝗮𝗰𝗮𝗱𝗲𝗺𝗶𝗮 𝗹𝗲𝗮𝗱𝗲𝗿𝘀 across R&D, discovery, biology, translational science, and clinical development, this is poised to be a must-attend event, deep-diving into the evolving macrophage-therapeutics landscape, exploring other indications, and tackling the most pressing industry challenges.💡   𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝘁𝗵𝗲 𝗙𝘂𝗹𝗹 𝗣𝗿𝗼𝗴𝗿𝗮𝗺 ➡️ https://ter.li/3pt48z   This is an incredible opportunity to unlock the full potential of your own macrophage therapeutics, with insights from 𝗖𝗮𝗿𝗶𝘀𝗺𝗮 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀, 𝗘𝗹𝗽𝗶𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝗕𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀, 𝗝𝗼𝗵𝗻 𝗛𝗼𝗽𝗸𝗶𝗻𝘀 𝗦𝗰𝗵𝗼𝗼𝗹 𝗼𝗳 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲, 𝗔𝗟𝗫 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆, 𝗩𝗲𝗿𝘀𝗲𝗮𝘂 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀, and many more!🔓   𝗝𝗼𝗶𝗻 𝘂𝘀 𝗶𝗻 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 ➡️ https://ter.li/l16k0n   #MacrophageDirectedTherapiesSummit